|
業務類別
|
Biotechnology |
|
業務概覽
|
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases. |
| 公司地址
| 1500 District Avenue, Burlington, MA, USA, 01803 |
| 電話號碼
| +1 617 600-7373 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.minervaneurosciences.com |
| 員工數量
| 7 |
| Mr. Frederick W. Ahlholm |
Senior Vice President, Chief Financial Officer, Principal Accounting Officer and Secretary |
美元 467.49K |
23/04/2026 |
| Dr. Remy Luthringer, PhD |
Executive Chairman of the Board and Chief Executive Officer |
美元 675.03K |
23/04/2026 |
| Mr. James Joseph O’Connor |
Chief Business Officer, Director and General Counsel |
-- |
02/04/2026 |
|
|
| Mr. Hans Peter Hasler |
Independent Director |
23/04/2026 |
| Mr. Jan van Heek |
Independent Director |
23/04/2026 |
| Dr. Remy Luthringer, PhD |
Executive Chairman of the Board and Chief Executive Officer |
23/04/2026 |
| Dr. Fouzia Laghrissi-Thode, M.D. |
Independent Director |
23/04/2026 |
| Dr. David J. Kupfer, M.D. |
Lead Independent Director |
23/04/2026 |
| Dr. Inderjit Kaul, M.D.,M.P.H. |
Director |
23/04/2026 |
| Mr. James Joseph O’Connor |
Chief Business Officer, Director and General Counsel |
02/04/2026 |
|
|
|
|
